1887

Abstract

Multi-drug-resistant tuberculosis (MDR-TB) is an emerging global challenge. Ethiopia is one of the 20 top countries with the highest estimated numbers of incidents of MDR-TB. Recently, the World Health Organization warned that drug-resistant TB is escalating and called for concerted action to reduce the spread of drug resistance.

The current study investigated MDR-TB in patients receiving first-line anti-TB drug treatment and associated factors.

The study aimed to determine the prevalence of MDR-TB and its associated factors among smear-positive pulmonary TB patients receiving first-line anti-TB drug treatment.

An institution-based cross-sectional study was employed. All data were collected from laboratory result log books and information via a questionnaire. Samples from 205 smear-positive pulmonary TB patients were selected among first-line drug treatment by a systematic sampling method. Specimens were transported to Felege Hiwot referral hospital laboratory for GeneXpert testing. Factors associated with an outcome variable in binary multi-variable logistic regression analysis at <0.05 were considered statistically significant variables. An ethical approval letter was taken to the respective health facility and written consent was obtained from each participant.

The overall prevalence of MDR-TB was 9.3 % (95 % CI, 5.4 13.7 %). Sign and symptom experience of anti-TB drug side effects [adjusted odds ratio (AOR)=0.18, 95 % CI=0.03–0.99, =0.049] and co-morbidity (AOR=0.03, 95 % CI=0.01–0.55, =0.02) were statistically associated with the development of MDR-TB infection

The prevalence of MDR-TB was high (9.3 %) and contributed highly to new cases (8.3 %). Factors associated with MDR-TB were previous treatment, co-morbidity and laboratory diagnosis method prior to TB treatment. Therefore, this finding aims to maximize early detection and treatment, strengthening TB infection control, and proper implementation of directly observed therapy short course recommendations to reduce the burden of MDR-TB.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001775
2023-12-15
2024-07-19
Loading full text...

Full text loading...

References

  1. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO; 2015
  2. WHO treatment guidelines for drug-resistant tuberculosis (Update 2016). Geneva, Switherland WHO/HTM/TB/201604: WHO; 2016
  3. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NTN et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008; 4:e1000034 [View Article] [PubMed]
    [Google Scholar]
  4. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68:2240–2246 [View Article] [PubMed]
    [Google Scholar]
  5. Global tuberculosis report Global Tuberculosis Report 2019 2019
    [Google Scholar]
  6. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. WHO; 2018 p 9241550236
  7. Hsueh P-R. World Health Day 2011--antimicrobial resistance: no action today, no cure tomorrow. J Formos Med Assoc 2011; 110:213–214 [View Article]
    [Google Scholar]
  8. Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S et al. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis 2015; 15:461 [View Article]
    [Google Scholar]
  9. Brhane M, Kebede A, Petros Y. Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist 2017; 10:75–83 [View Article]
    [Google Scholar]
  10. Esmael A, Ali I, Agonafir M, Endris M, Getahun M. Drug resistance pattern of Mycobacterium tuberculosis in Eastern Amhara Regional State, Ethiopia. J Microb Biochem Technol 2014; 06:75–79 [View Article]
    [Google Scholar]
  11. Abebe G, Abdissa K, Abdissa A, Apers L, Agonafir M et al. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes 2012; 5:225 [View Article]
    [Google Scholar]
  12. Yimer SA, Agonafir M, Derese Y, Sani Y, Bjune GA et al. Primary drug resistance to anti-tuberculosis drugs in major towns of Amhara region, Ethiopia. APMIS 2012; 120:503–509 [View Article]
    [Google Scholar]
  13. Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D et al. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS One 2018; 13:e0197737 [View Article]
    [Google Scholar]
  14. Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis 2017; 17:219 [View Article]
    [Google Scholar]
  15. Kebede A. Second round national anti-tuberculosis drug resistance surveillance –422 Ethiopia; 2015
  16. Global tuberculosis report 2013. WHO; 2013
  17. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis 2012; 16:805–811 [View Article]
    [Google Scholar]
  18. Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S et al. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia. BMC Infect Dis 2015; 15:1–6
    [Google Scholar]
  19. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005; 60:130–135 [View Article]
    [Google Scholar]
  20. Hirpa S, Medhin G, Girma B, Melese M, Mekonen A et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health 2013; 13:1–9 [View Article]
    [Google Scholar]
  21. Abate D, Taye B, Abseno M, Biadgilign S. Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia. BMC Res Notes 2012; 5:1756–0500 [View Article]
    [Google Scholar]
  22. Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A et al. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. INT J Tuberc Lung Dis 2010; 14:1259–1265 [PubMed]
    [Google Scholar]
  23. Hamusse SD, Teshome D, Hussen MS, Demissie M, Lindtjørn B. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health 2016; 16:593 [View Article]
    [Google Scholar]
  24. Meskel DW, Abate G, Lakew M, Goshu S, Aseffa A. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Ethiop Med J 2008; 46:219–225
    [Google Scholar]
  25. Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-Saharan Africa: how strongly associated with previous treatment and HIV co-infection?. Ethiop J Health Sci 2013; 23:271–282 [View Article]
    [Google Scholar]
  26. Abebe G, Abdissa K, Abdissa A, Apers L, Agonafir M et al. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes 2012; 5:1–6
    [Google Scholar]
  27. Johnson R, Streicher EM, Louw GE, Warren RM, Helden PD et al. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8:97–112
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001775
Loading
/content/journal/jmm/10.1099/jmm.0.001775
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error